Expert Interview
Discussing Arcellx Inc's anito-cel and how it compares to other therapies for the Treatment of Multiple Myeloma
Ticker(s): ACLX, JNJ, GILD, LEGNInstitution: University of Rochester
- Associate Professor of Medicine and Clinical Director of Multiple Myeloma at The University of Rochester.
- Manages 200 patients with multiple myeloma and also treats patients with other plasma cell disorders.
- Research interests include multiple myeloma and studying disease progression to develop therapies for multiple myeloma prevention.
Describe your background and practice setting
Added By: wilson_adminHow many patients with multiple myeloma do you manage?
Added By: wilson_adminWhat are your thoughts on the potential of Carvykti and Anito-cel?
Added By: wilson_adminWhere do you see CART therapies fitting into the future treatment algorithm of multiple myeloma?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
